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Daptomycin: a new treatment for insidious
infections due to gram-positive pathogens
Philippe Cottagnoud
Department of Internal Medicine, Inselspital Bern, Switzerland
Daptomycin, a new lipopeptide antibiotic, is
highly bactericidal against the majority of Gram-
positive human pathogens, including methicillin-
resistant Staphylococcus aureus (MRSA) and vanco -
mycin-resistant enterococci. Its mechanism of
 action is unique resulting in the destruction of the
membrane potential without lysing the cell wall.
The mechanism of action of daptomycin, its anti-
bacterial spectrum, the development of resistance
and pre- and clinical studies are discussed in this
review.
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Summary
The treatment of infections due to Gram-
positive cocci, especially Staphylococcus aureus, co-
agulase-negative staphylococci and enterococci
represents an increasing challenge for clinicians
in the hospital environment and in the outpatient
setting. Based on a survey of the Surveillance and
Control of Pathogens of Epidemiologic Impor-
tance (SCOPE), which has monitored blood-
stream infections in hospitals of the United States
from 1995 to 1998, 60% of nosocomial blood-
stream infections have been caused by Gram-pos-
itive pathogens [1]. Coagulase-negative staphylo-
coccal strains caused about 32% of bloodstream
infections, followed by Staphylococcus aureus with
25.7% and enterococci with 11.1%. In a study in-
cluding 24 179 cases of bloodstream infections
conducted by Wisplinghoff et al. [2] between
1995 and 2002, an increase of resistant isolates of
all major Gram-positive strains was documented,
jeopardising the use of standard antibiotics. This
paper presents the actual epidemiological situa-
tion for the essential Gram-positive pathogens.
Methicillin-resistant Staphylococcus aureus
(MRSA), which has been an exclusive nosocomial
pathogen for decades [3], has begun to spread
within the outpatient community. The National
Nosocomial Infections Surveillance (NNIS)
study reports a rate of 59.5% of MRSA among
Staphylococcus aureus infections in ICU patients in
the United States for the year 2004 [4]. Interest-
ingly, only a few clones are spreading throughout
the world and are responsible for the high resis -
tant rates. Recently, Oliviera et al. [5] were able to
identify five MRSA clones accounting for around
70% of the over 3000 MRSA isolates recovered in
hospitals mainly in Southern and Eastern Europe,
South America, and the USA. The common fea-
ture of MRSA strains is the presence of the mecA
gene, encoding the low affinity penicillin-binding
protein 2A conferring resistance against methi-
cillin and other beta-lactam antibiotics. Further-
more, MRSA are resistant to other antibiotic
classes, even to quinolones. Quinolone resistance
has become a hallmark of nosocomial MRSA. For
decades, vancomycin was the only effective treat-
ment for severe MRSA infections. Since 1996
however, strains with an intermediate resistance
to vancomycin (VISA: vancomycin-intermediate
Staphylococcus aureus), with MICs between 8 and
16 mg/L have been reported from Japan [6, 7] and
since 1997 from the United States [8]. VISA
strains harbour a thickened cell wall, trapping
vancomycin molecules and so preventing them
from reaching their targets, the cell wall precur-
sors on the outside of the plasma membrane [9].
More alarming are recent reports of vancomycin-
resistant Staphylococcus aureus with an MIC of 
64 mg/L [10, 11]. The mechanism of resistance is
based on a transfer of a transposon containing a
vanA gene originating from vancomycin-resistant
enterococci.
For decades, MRSA has been the paradigm of
a nosocomial microorganism, causing severe in-
fections. More recently however, it is evident 
that MRSA can be acquired in the community as
well. Community-acquired methicillin-resistant
Staphylococcus aureus infections usually occur in
otherwise healthy children and young adults and
represent an increasing problem worldwide [12].
A typical landmark of these community-acquired
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strains is the presence of the Panton-Valentine
leukocidin, a cytotoxin leading to the destruction
of host leukocytes and causing tissue necrosis. In
general, these strains are more susceptible to non-
beta-lactam antibiotics (eg, tretracyclines,
trimethoprim-sulfamethoxazole) than hospital-
acquired MRSA.
Until 1989, resistance to vancomycin was
non-existent in enterococci in the United States.
However, a dramatic increase in vancomycin-
resistant enterococci has occurred since 1990, 
primarily in ICUs. Nowadays, the rate of 
vancomycin-resistant enterococci has reached
around 30%, based on a recent NNIS report [4].
Interestingly, the vast majority of resistant strains
are E. faecalis. Wisplinghoff et al. reported resis -
tance rates around 70% in US hospitals for the
period from 2000 to 2002 [2]. Vancomycin-resis-
tant enterococci are able to alter the structure of
the vancomycin target (the cell wall precursors)
by exchanging an amino acid of the peptide side-
chain from D-alanine-D-alanine to D-alanine-
D-lactate. 
Streptococcus pneumoniae, a common colonis-
ing microorganism of the pharynx, has also be-
come resistant to penicillin and other antibiotic
classes. Resistance has been triggered by exposure
to antibiotics especially used for infections of the
upper respiratory tract. In the United States,
penicillin-resistance of pneumococci reached
40% in adults in a recent survey [13].
Confronted with the ubiquitous increase of
resistance rates of these major human pathogens
against conventional antibiotics, there is a need to
develop new antibiotics which are highly active
against Gram-positive microorganisms. Among
the candidates, daptomycin, a new lipopeptide, is
one of the most promising compounds. Here we
present its mechanisms of action, its antimicrobial
spectrum and its effectiveness in Gram-positive
infections.
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Structure and mechanism of action 
Daptomycin is a cyclic lipopeptide antibiotic
produced by fermentation of Streptomyces
roseosporus [14]. Usually S roseosporus produces a
variety of lipopeptides with different long-chain
fatty acid tails. Daptomycin, which contains a 
C10-lipid side-chain, is produced by addition of de-
canoic acid to the growth medium during fermen-
tation [15]. Daptomycin contains 13 aminoacids
of which 10 form a cyclic frame linked by an ester
bond between the terminal kynurenine and the
hydroxyl group of threonine (fig. 1).
The predominantly acidic nature and the neg-
ative charge (3-) at neutral pH are responsible for
the high solubility in aqueous solutions of this 
antibiotic. Its lipid tails and some hydrophobic
amino acids warrant amphipathic properties. 
The antibacterial activity of daptomycin is
highly calcium-dependent. Its antibacterial effi-
cacy is optimal in the presence of a Ca2+ concen-
tration around 1.25 mM (50 mg/L) and negligible
in absence of Ca2+ [16–18]. This crucial Ca2+ level
corresponds to levels usually measured in human
serum [19]. The calcium-induced changes in the
daptomycin structure lead to a relative increase of
the hydrophobic surface of 5% and promote dap-
tomycin oligomerisation [20]. Although the
mechanism of action of daptomycin has not been
completely clarified, the main target is the bacte -
rial plasma membrane. The most conceivable sce-
nario is a multistep process as proposed by Silver-
man et al. [21]. In a first step, calcium binds 
daptomycin which itself is weakly bound to the
cytoplasmatic membrane. This leads to confor -
mational changes and insertion into the plasma
membrane and subsequent oligomerisation of
daptomycin. In a second step, this oligomerisation
of daptomycin builds channels causing membrane
leakage and outflow of intracellular potassium. 
The bactericidal activity of daptomycin is
based on the depolarisation of the membrane
Figure 1
Structure of 
daptomycin.
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which leads to cell death. Jung et al. [20] proposed
a more complex model and suggested that the
bactericidal action of daptomycin is not solely due
to the membrane depolarisation but that dapto-
mycin also interacts with several bacterial compo-
nents, such as cell wall, various enzymes, RNA
and DNA, similarly to the multilevel mechanisms
of action of antibacterial cationic peptides [22–
25]. The mechanism of action of daptomycin is
summarised in figure 2.
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Figure 2
Scheme of the 
mechanism of action
of daptomycin.
Antibacterial spectrum
Daptomycin is efficacious in vitro against a
broad range of aerobic and anaerobic Gram-posi-
tive microorganisms, including multi-drug resis -
tant strains [19, 26–35]. The MIC ranges, MIC50
and MIC90 for the different isolates are sum-
marised in table 1. One of the most striking fea-
tures of daptomycin is its activity against the most
difficult to treat Gram-positive microorganisms,
especially methicillin-resistant Staphylococcus au-
reus (MRSA), glycopeptide-intermediate S. aureus
(GISA) and vancomycin-resistant enterococci
(VRE). For Staphylococcus species the MIC90
ranges lie around 0.5 mg/L. Enterococci (van-
comycin-resistant strains included) are slightly
less sensitive with MIC90 between 1 and 4 mg/L.
In general, daptomycin has the highest activity
against streptococci. Daptomycin is also effective
in vitro against some anaerobic strains (eg,
clostridium und propionibacterium species),
against rare Gram-positive microorganisms, as
corynebacterium, and some bacillus species. Dap-
tomycin is also active against Listeria species with
MIC around 2 mg/L. The MIC breakpoints have
been determined by the European Committee on
Antimicrobial Susceptibility Testing (EUCAST)
for staphylococci and streptococci (except for
pneumococci) as follows: sensitivity: 1 mg/L and
resistance >1 mg/L [36].
Daptomycin is not active against Gram-nega-
tive bacteria because of its inability to penetrate
the outer membrane of these microorganisms [37,
38].
Resistance
In general, the widespread use of antibiotics
represents a major risk for the development of re-
sistance. The risk of bacterial resistance to dapto-
mycin is much less pronounced than for conven-
tional antibiotics due to its unique mechanism of
action. Gram-positive microorganisms have a low
potential for developing resistance against dapto-
mycin in vitro. Resistant mutants do not emerge
spontaneously and more than 20 passages in pres-
ence of daptomycin are needed to produce a small
number of resistant isolates [39]. Many mutants
showed significant growth defects and other mu-
tants had lost their virulence. Recently, Kaatz et al.
[40] demonstrated that in vitro development of
daptomycin resistance in S. aureus correlated with
the loss of an 81 kDa membrane protein. One
conceivable explanation is that this protein inter-
acts directly with daptomycin in the plasma mem-
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Species of Microorganism N MIC Range MIC50 MIC90 Reference
Staphylococcus species
S. aureus 3202 ≤0.12–2 0.25 0.5
Coagulase-negative Staphylococcus spp. 838 ≤0.12–2 0.25 0.5
Enterococcus species
E. faecalis (vancomycin-susceptible) 626 ≤0.12–4 1 1
E. faecalis (vancomycin-resistant) 20 0.25–1 1 1
E. faecium (vancomycin-susceptible) 97 ≤0.12–8 2 4
E. faecium (vancomycin-resistant) 55 0.25–4 2 4
Streptococcus species
viridans group streptococci 149 ≤0.12–1 0.25 0.5 
Other b-haemolytic streptococci (including 247 ≤0.12–0.5 ≤0.12 0.25 
Group A, B, C, Group F, Group G and 
S. dysgalactiae)  
Anaerobes
Clostridium difficile 102 0.125–2 0.5 1
Clostridium perfringens 101 0.06–8 0.5 2
Propionibacterium acnes 117 0.25–1 0.5 1
Finegoldia magna 101 ≤0.015–2 0.5 1
Rare Gram-positives
Corynebacterium species 21 ≤0.03–8 ≤0.03 1
Bacillus species 10 ≤0.12–8 1 2
Listeria species 18 0.25–4 2 2
Table 1
In vitro activity 
of daptomycin
against gram-
positive organisms
brane. Friedman et al. [41] described in clinical
daptomycin-resistant isolates point mutations in
the mprF gene and nucleotide insertion in the 
yycF gene, encoding a lysylphosphatidylglycerol
synthetase and a histidine kinase, respectively. In
the clinical setting the emergence of daptomycin-
resistance is low until now. In a prospective study
including 120 patients treated with daptomycin
for bacteraemia and endocarditis caused by
Staphylococcus aureus, resistant isolates were docu-
mented in six cases (5%) with MICs increased
during daptomycin treatment [42]. Following
 several years of experience under experimental
 settings however, development of resistance
against daptomycin has been observed in clinical
isolates of MRSA during daptomycin therapy 
[43–45]. A matter of increasing concern is the
cross-resistance between vancomycin and dapto-
mycin described in Staphylococcus aureus, although
the strains were not exposed to daptomycin. The
underlying mechanism is not clear but might be
due to cell wall thickening of vancomycin-resis-
tant strains, preventing daptomycin to reach the
plasma membrane [9, 46, 47].
Pharmacodynamics
Once-daily dosing of daptomycin increases
the antibacterial efficacy and minimises the side
effects [48]. Daptomycin is effective in a dose-
dependent manner with a long half-life around
8 hours and produces a post-antibiotic effect up to
6.8 hours [49]. Dosed once a day, daptomycin ex-
hibits linear pharmacokinetics with minimal drug
accumulation. Daptomycin is excreted primarily
renally, with the majority of the drug remaining
intact in the urine [48]. The penetration of dapto-
mycin into the tissues varies from 9% into the
lung [50, 51] to 68% into blister fluid [52]. Dapto-
mycin penetrates only marginally (2%) into the
cerebrospinal fluid of non-infected rabbits [53]
but increases to 6% during pneumococcal menin-
gitis [54]. Plasma clearance is low, due in part to
high protein binding (87–94%) [55].
Streit JM.  J. Antimicrob.
Chemother. 2004;53:669–674
Streit JM.  J. Antimicrob.
Chemother. 2004;53:669–674
Streit JM.  J. Antimicrob.
Chemother. 2004;53:669–674
Tyrrell KL. Antimicrob Agents
Chemother. 2006;50:2728–2731.
Goldstein E. Antimicrob Agents
Chemother. 2003;47:337–342
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093-099 Cott 12045.qxp  18.2.2008  15:02 Uhr  Seite 96
97S W I S S  M E D  W K LY 2 0 0 8 ; 13 8 ( 7 – 8 ) : 9 3 – 9 9 ·  w w w. s m w. ch
Clinical and experimental studies
Daptomycin is now approved by the FDA for
the use in adults with complicated soft tissue and
skin infections caused by S. aureus, streptococci
and E. faecalis (vancomycin-susceptible strains
only). In two international randomised phase III
studies involving 1092 patients with complicated
skin and skin-structure infections, daptomycin
was not inferior to the comparators (penicillinase-
resistant penicillins or vancomycin) with success
rates of 83.4% and 84.2%, respectively. In the
daptomycin group, 63% of the patients required
only 4 to 7 days of therapy compared with 33% in
the comparator regimen [56]. A recent review
very carefully analysed the efficacy and safety of
daptomycin in the treatment of bone and joint in-
fections with cure rates about 81% [57].
Further two phase III studies were conducted
to evaluate daptomycin in hospitalised patients
with community acquired pneumonia (CAP). The
objective of non-inferiority compared to ceftriax-
one was not achieved [58, 59]. The cause of the
failure of daptomycin in CAP was probably due to
sequestration and inactivation of daptomycin by
pulmonary surfactant [50].
Daptomycin is also FDA approved for bacter-
aemia and right sided endocarditis caused by
MSSA or MRSA based on the data from an open-
label randomised trial. Patients with S. aureus bac-
teremia with or without endocarditis were ran-
domised as follows: 120 were treated with dapto-
mycin (6 mg/kg) and 115 with a standard regimen
(gentamicin plus either antistaphylococcal peni-
cillin or vancomycin). In this study, daptomycin
met the criterion of non-inferiority with a simi-
larly successful outcome (44.2% for daptomycin
versus 41.7% for the standard regimen). Most pa-
tients with persistent or relapsing infections had
complicated bacteraemia associated with osteo -
myelitis or indwelling protheses. The adverse
events were slightly but not significantly less fre-
quent in the standard regimen group. However, in 
the standard regimen significantly higher renal
impairment (18.1% vs 6.7% in the daptomycin
group) was documented. Falagas et al. [60] re-
cently published a systematic review of the litera-
ture underlining the effectiveness of daptomycin
for the treatment of endocarditis with or without
bacteraemia.
In the experimental rat endocarditis model
daptomycin was very efficacious in the treatment
of endocarditis due to susceptible and multi-resis-
tant enterococci. Daptomycin was more effica-
cious than teicoplanin against the glycopeptide-
susceptible strain and superior to all comparators
against an ampicillin- and vancomycin-resistant
strain [61].
The efficacy of daptomycin was also demon-
strated against penicillin-resistant and penicillin-
and quinolone-resistant pneumococci in the ex-
perimental rabbit meningitis model. Against both
strains daptomycin was superior to the standard
regimen based on a combination of vancomycin
with ceftriaxone. Daptomycin managed to steril -
ise the CSFs of all animals within four hours [54].
In the same experimental model, daptomycin
was superior to vancomycin against a methicillin-
susceptible S. aureus [53]. Addition of rifampicin
to daptomycin drastically improved its efficacy in
staphylococcal meningitis (unpublished data).
Combination of daptomycin with ceftriaxone, as
potential empirical therapy, has also been success-
fully tested in this model (Abstract, 46th Inter-
science Conference on Antimicrobial Agents and
Chemotherapy, San Francisco, September 2006).
The bactericidal but non-bacteriolytic property of
daptomycin, which is a prerequisite for an ideal
treatment for pneumococcal meningitis, has also
been demonstrated in this model. Compared to
ceftriaxone, a bacteriolytic antibiotic, daptomycin
led to a minimal release of cell wall fragments, a
major virulence factor of pneumococci during
meningitis. At the end of daptomycin treatment
no morphological alterations of the pneumococci
could be detected by electronmicroscopy [62]. In
the infant rat meningitis model, daptomycin pro-
duced significantly less cytokines (metallopro-
tease-9 and TNF-a) and cortical damage than
ceftriaxone during pneumococcal meningitis [62,
63].
Conclusions
Daptomycin’s unique mechanism of action,
low propensity to induce resistance and highly
bactericidal activity against major Gram-positive
pathogens qualify daptomycin to play a major role
in the treatment of infections caused by insidious
Gram-positive pathogens. Its efficacy in the treat-
ment of complicated skin infections is well estab-
lished. Also promising data in the treatment of
staphylococcal bacteraemia have been recently
published and resulted in a second FDA indica-
tion. Its role in the treatment of bacterial menin-
gitis, as monotherapy or combined with ceftriax-
one is unclear, but the preliminary data obtained
in the experimental rabbit model deserve further
clinical investigation.
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